Selective estrogen receptor modulation
- 1 March 2004
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 5 (3), 207-213
- https://doi.org/10.1016/s1535-6108(04)00059-5
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Selective Estrogen Receptor Modulators 4-Hydroxytamoxifen and Raloxifene Impact the Stability and Function of SRC-1 and SRC-3 Coactivator ProteinsMolecular and Cellular Biology, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17 -EstradiolJNCI Journal of the National Cancer Institute, 2001
- Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancerOncogene, 2000
- Effects of anti-estrogens on bone in castrated and intact female ratsBreast Cancer Research and Treatment, 1987
- Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma modelEuropean Journal of Cancer (1965), 1980